According to a large observational study published in Alzheimer’s & Dementia, widely used osteoporosis drugs called nitrogen-containing bisphosphonates are linked to a 16% lower risk of developing Alzheimer’s disease and related dementias compared to untreated patients. Researchers at the University of Hong Kong analyzed citywide electronic medical records from 121,492 adults aged 60 and older between 2005 and 2020, finding that patients taking these bone-strengthening medications also experienced a 24% lower risk of dementia than those receiving other osteoporosis treatments.
Understanding Nitrogen-Containing Bisphosphonates and Dementia Risk
Nitrogen-containing bisphosphonates—commonly known as NBPs, which include medications such as alendronate, ibandronate, risedronate, and zoledronate—are prescribed to slow bone loss and minimize fracture risks in patients suffering from osteoporosis. According to study author Ching-Lung Cheung, an associate professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed), the research team estimated that treating 48 patients with NBPs for five years could potentially prevent one case of dementia.
Did you know? Over 55 million people worldwide are currently living with dementia, a figure projected by the World Health Organization to reach 139 million by 2050. Repurposing widely available drugs like NBPs offers a potential avenue for addressing this growing global health challenge.
The Biological Overlap Between Bone and Brain Health
Osteoporosis and dementia frequently affect the same aging populations and share distinct risk factors, including advanced age, female sex, and reduced physical activity, according to the HKUMed research team. Previous work led by the same department established that osteoporosis and fractures act as independent risk factors for dementia. Emerging biological evidence indicates that cellular pathways affected by NBPs may also play a role in the pathogenesis of Alzheimer’s disease and related dementias, providing an empirical basis for investigating their neuroprotective potential.
Study Limitations and Next Steps in Clinical Research
Despite the promising findings, Ching-Lung Cheung emphasized that the study’s observational design means the results do not definitively prove that bisphosphonate use directly reduces dementia risk. Additional limitations noted by the researchers include a lack of baseline cognitive testing, missing data on over-the-counter calcium and vitamin D usage, and the fact that the study population was exclusively Chinese, leaving questions about generalizability to other populations. The research team stresses that these findings do not yet justify prescribing NBPs specifically for dementia prevention, calling instead for rigorous randomized clinical trials.
Pro Tip: Patients currently managing osteoporosis or fragility fractures should consult healthcare professionals to weigh the overall benefits and risks of their prescribed medication regimen rather than seeking bone medications for cognitive outcomes.
Frequently Asked Questions
What are nitrogen-containing bisphosphonates?
Nitrogen-containing bisphosphonates (NBPs) are medications like alendronate and zoledronate used to slow bone loss and treat osteoporosis in older adults.
Does taking osteoporosis medication prevent Alzheimer’s disease?
Not definitively. While a large Hong Kong study linked NBP use to a lower risk of dementia, researchers emphasize that clinical trials are required to confirm whether the drugs directly cause this protective effect.
Who led the recent osteoporosis and dementia study?
The research was led by Ching-Lung Cheung and Dr. Sing Chor-wing from the Department of Pharmacology and Pharmacy at the University of Hong Kong.
To stay updated on the latest health research and medical breakthroughs, subscribe to our health newsletter and explore more stories on our Health Channel.